To observe the clinical effect of bupleurum Liver-Soothing Powder combining with Rabeprazole Sodium Enteric-coated Tablets for treating gastro-esophageal reflux disease. Methods:A total of 90 patients with gastro-esophageal reflux disease in our hospital from March 2013 to April 2015 were selected and randomly divided into the control group(45 patients) and the treatment group(45 patients). The control group had Rabeprazole Sodium Enteric-coated Tablets, while the treatment group had bupleurum Liver-Soothing Powder on the basis treatment of the control group.The treatment lasted for 2 course, a course lasted for 4 weeks. The clinical symptom integral, the clinical curative effect,the esophageal mucosal lesions classification,the adverse reactions and the recurrence rate were compared between the groups. Results:After treatment,the treatment group of heartburn integrals, anti-acid integrals, chest discomfort integrals and anti-food integrals were significantly lower than the control group（P<0.05）.The total effectiveness of the treatment group was 90.2 %, which was significantly higher than the control group 73.6%, and the difference was statistically significant (χ2=4.87, P<0.05).The treatment group esophageal mucosal lesions classification improved more comparing with the control group, and the difference was statistically significant (P<0.05). Both of the groups had less adverse reactions and the difference was not statistically significant (P>0.05). Three months later after the treatment, the treatment group recurrence rate was 6.67%, it was significantly 26.67% lower than the control group (χ2=6.48，P<0.05）.Conclusion:Bupleurum Liver-Soothing Powder with Rabeprazole Sodium Enteric-coated Tablets has significant effects on gastro-esophageal reflux disease，and is better than Rabeprazole Sodium Enteric-coated Tablets, worthwhile for spreading in clinical practice.